Radioactive Label Patents (Class 436/504)
-
Patent number: 6361954Abstract: The invention pertains to novel genes which function in the regulation of DNA replication and/or entry of a cell into mitosis. Tile invention also pertains to novel proteins encoded by the genes described herein, antibodies which bind the encoded protein, and homologs of the novel genes which function in regulation of DNA replication and/or entry of a cell into mitosis find hybridize to the DNA sequence of the novel genes. The invention also includes methods for determining the presence of a proliferative disorder comprising determining the presence of level of hscdc6.Type: GrantFiled: October 30, 1998Date of Patent: March 26, 2002Assignees: Cold Spring Harbor Laboratory, The University of Texas SystemInventors: Bruce Stillman, R. Sanders Williams, Juan R. Mendez
-
Patent number: 6361957Abstract: Determination of a synaptosomal D-serine transporter and use of an assay method for discovering inhibitors thereof to be used in the treatment of psychotic disorders.Type: GrantFiled: August 3, 1999Date of Patent: March 26, 2002Assignee: Glytech, Inc.Inventor: Daniel C. Javitt
-
Patent number: 6355644Abstract: Disclosed are benzylpiperazinyl-indolinylethanone compounds which are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents. Pharmaceutical compositions, including packaged pharmaceutical compositions, are further provided. Compounds of the invention are also useful as probes for the localization of GABAA receptors in tissue samples.Type: GrantFiled: June 14, 2000Date of Patent: March 12, 2002Assignee: Neurogen CorporationInventors: He Zhao, Andrew Thurkauf
-
Patent number: 6350582Abstract: A method for the direct analysis of the presence of an analyte which becomes embedded in keratinized structures, e.g., hair, fingernails and toenails, from the bloodstream of a subject which comprises preparing a mixture containing dithiothreitol or dithioerythritol (“DTT”), an enzyme suitable for the digestion of the keratin structure and a sample of the keratin structure; permitting the enzyme to digest the sample of keratin structure to form a digest solution, followed by the addition of a salt of a metal of copper, zinc, manganese, iron, lead, cadmium, mercury, silver and cobalt to deactivate the DTT; and finally subjecting the digest solution to analysis to determine the presence of the analyte in the keratin structure sample. The protease enzymes papain, chymopapain, and proteinase K are preferred for use in the invention.Type: GrantFiled: February 7, 2000Date of Patent: February 26, 2002Assignee: Psychemedics CorporationInventor: Werner Andreas Baumgartner
-
Patent number: 6342354Abstract: The present invention relates to a linear DNA vector and to a method for identifying chromosomal regions having a physical proximity within a living cell, and/or for locating in chromosomes of a living cell a DNA double strand break having a physical proximity with a known non-repetitive DNA sequence. The linear DNA vector has a first end which comprises a nucleotide sequence capable of homologous recombination to a first region of a cell chromosome which comprises a known non-repetitive DNA sequence. The linear DNA vector also has a second end which comprises a nucleotide sequence non-homologous to the chromosomes of the cell and being capable of illegitimate integration with a second region of a chromosome in physical proximity to the first chromosomal region.Type: GrantFiled: December 3, 1999Date of Patent: January 29, 2002Assignees: Université de Montréal, Centre Hospitalier de l'Universitéde Montréal (CHUM)Inventors: Pierre Chartrand, Graham Dellaire
-
Patent number: 6316204Abstract: The present invention relates to methods and compositions for the diagnosis, prevention, and treatment of tumor progression in cells involved in human tumors such as melanomas, breast, gastrointestinal, lung, and bone tumors, various types of skin cancers, and other neoplastic conditions such as leukemias and lymphomas. Genes are identified that are differentially expressed in benign (e.g., non-malignant) tumor cells relative to malignant tumor calls exhibiting a high metastatic potential. Genes are also identified via the ability of their gene products to interact with gene products involved in the progression to, and/or aggressiveness of, neoplastic tumor disease states. The genes and gene products identified can be used diagnostically or for therapeutic intervention.Type: GrantFiled: December 7, 1999Date of Patent: November 13, 2001Assignee: Millennium Pharmaceuticals, Inc.Inventor: Andrew W. Shyjan
-
Patent number: 6303299Abstract: The invention relates to a method for studying translation initiation and for identifying potential inhibitors of translation initiation by expressing proteins in the presence of misacylated suppressor tRNAs.Type: GrantFiled: May 13, 1998Date of Patent: October 16, 2001Assignee: University of Virginia Patent FoundationInventors: Sidney M. Hecht, Vladimir Karginov, Andrei V. Karginov
-
Patent number: 6294347Abstract: Soluble and membrane-bound forms of human Fc&ggr;RIII are provided, together with nucleic acids capable of encoding the same. Soluble Fc&ggr;RIIIs are useful in ameliorating the serum platelet deficiency associated with immune thrombocytopenic prupura. Cells expressing membrane-bound Fc&ggr;RIIIs are useful components in assays for serum immune complexes.Type: GrantFiled: January 19, 1999Date of Patent: September 25, 2001Assignee: Applied Research Systems ARS Holding N.V.Inventors: Gary A. Peltz, Kevin W. Moore
-
Patent number: 6284473Abstract: The present invention provides a method of determining the status of a multiple sclerosis patient, i.e., predicting the transition from a status of relapsing-remitting to a progressive phase of multiple sclerosis, comprising the step of measuring the amount of urinary p-cresol sulfate in the patient. The present invention also provides a method of determining the amount of lesions and total lesion area of a multiple sclerosis patient, comprising the step of measuring the amount of urinary p-cresol sulfate in the patient. Further provided is a method of monitoring myelination in a developing child, comprising the step of: measuring the amount of p-cresol sulfate in the urine of said child.Type: GrantFiled: October 6, 1999Date of Patent: September 4, 2001Assignee: UAB Research FoundationInventors: John Nicholas Whitaker, Robert David Kachelhofer, Edwin Luther Bradley, Jr., Sheila Loughran Burgard, Beverly Ann Layton, Anthony Thomas Reder, Wendy Jean Morrision, Guojun Zhao, Donald Winston Paty, Ligong Cao, Lori Coward, Patricia L. Jackson, Marion Kirk
-
Patent number: 6280964Abstract: The present invention generally provides peptides that comprise a recognition sequence motif for phosphotyrosine binding proteins. In particular, the present invention provides peptides which comprise a core sequence of amino acids, and analogs thereof, which are recognized and bound by the PTB (phosphotyrosine binding) domain. Also provided are methods of using the peptides of the invention in diagnostic, screening and therapeutic applications.Type: GrantFiled: April 14, 1995Date of Patent: August 28, 2001Assignee: The Regents of the University of CaliforniaInventors: William Michael Kavanaugh, Lewis T. Williams
-
Patent number: 6268221Abstract: The present invention relates to a mammalian melanocyte stimulating hormone receptor (MSH-R). The invention is directed toward the isolation, characterization and pharmacological use of a mammalian melanocyte stimulating hormone receptor, the gene corresponding to this receptor, a recombinant eukaryotic expression construct capable of expressing a mammalian melanocyte stimulating hormone receptor in cultures of transformed eukaryotic cells and such cultures of transformed eukaryotic cells that synthesize mammalian melanocyte stimulating hormone receptor. The invention also provide methods for screening MSH-R agonists and antagonists in vitro using preparations of receptor from such cultures of eukaryotic cells transformed with a recombinant eukaryotic expression construct comprising the MSH-R receptor gene. The invention specifically provides human and mouse MSH-R genes.Type: GrantFiled: December 1, 1998Date of Patent: July 31, 2001Assignee: Oregon Health & Science UniversityInventors: Roger D. Cone, Kathleen G. Mountjoy
-
Patent number: 6265160Abstract: Agents which inhibit the Jak-Stat signal transduction pathway are identified in order to identify candidate drugs for treatment of proliferative disorders. Identification methods are alternatively based on inhibiting the interaction of: (1) the activated Stat3 and Stat5 transcription factors with an electrophoretic mobility shift assay probe, or (2) the Stat3 or Stat5 proteins with the IL-2R&bgr; chain of the IL-2 receptor.Type: GrantFiled: January 7, 1998Date of Patent: July 24, 2001Assignee: The United States of America as represented by the Department of Health and Human ServicesInventor: Warren J. Leonard
-
Patent number: 6261789Abstract: The invention provides methods for detecting the presence of a PSCA protein comprising contacting the sample with PSCA antibodies designated 1G8 (ATCC No. HB-12612), 2A2 (ATCC No. HB-12613), 2H9 (ATCC No. HB-12614), 3C5 (ATCC No. HB-12616), 3E6 (ATCC No. HB12618), 3G3 (ATCC No. HB-12615), or 4A10 (ATCC No. HB-12617).Type: GrantFiled: February 17, 1999Date of Patent: July 17, 2001Assignee: The Regents of the University of CaliforniaInventors: Robert E. Reiter, Owen N. Witte
-
Publication number: 20010006619Abstract: The present invention relates to a class of compounds having affinity for certain cancer cells, e.g. lung carcinomas, colon carcinomas, renal carcinomas, prostate carcinomas, breast carcinomas, malignant melanomas, gliomas, neuroblastomas and pheochromocytomas. The compounds of the present invention can also bind with high specificity to cell surface sigma receptors and can therefore be used for diagnostic imaging of any tissue having an abundance of cells with sigma receptors. The present invention provides such compounds as agents for diagnostic imaging and for detecting and treating tumors containing the cancer cells described above.Type: ApplicationFiled: January 5, 2001Publication date: July 5, 2001Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.Inventors: Christy S. John, Jesse Baumgold, John G. McAfee, Terry Moody, Wayne Bowen
-
Patent number: 6224849Abstract: The present invention concerns the compounds of formula the N-oxide forms, the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein X is O or S; n is 2, 3, 4 or 5; R1 is hydrogen, C1-6alkyl, C1-6alkyloxy or halo; R2 is hydrogen, C1-6alkyl, phenyl, phenylC1-6alkyl or phenylcarbonyl; R3 and R4 each independently are selected from hydrogen, halo, nitro, C1-6alkyl, C1-6alkyloxy, haloC1-6alkyl, aminosulfonyl, mono- or di(C1-4alkyl)aminosulfonyl; or R3 and R4 may also be taken together to form a bivalent radical of formula —CH═CH—CH═CH—; it further relates to processes for their preparation, compositions comprising them as well as their use as a medicine; compounds of formula (I) containing a radioactive isotope; a process of marking dopamine D4 receptor sites; and a process for imaging an organ are disclosed.Type: GrantFiled: June 27, 2000Date of Patent: May 1, 2001Assignee: Janssen Pharmaceutica N.V.Inventors: Ludo Edmond Josephine Kennis, Josephus Carolus Mertens, Serge Maria Aloysius Pieters
-
Patent number: 6197278Abstract: A method of imaging apoptosis in vivo, using radiolabeled annexin, is described.Type: GrantFiled: April 29, 1998Date of Patent: March 6, 2001Assignees: The Board of Trustees of the Leland Stanford Junior University, University of WashingtonInventors: Francis G. Blankenberg, H. William Strauss, Jonathan F. Tait, Peter D. Katsikis
-
Patent number: 6187566Abstract: This invention relates to methods of amplifying nucleic acids to minimize contamination by products of earlier amplification reactions. More particularly, it relates to methods of using nucleic acid labels that inhibit further amplification of the amplicon, and compositions that are useful to accomplish this task. In particular, the present invention relates to photoreactive complexes of a binding ligand, a binding enhancer and a label.Type: GrantFiled: March 9, 1999Date of Patent: February 13, 2001Assignee: Applied Gene Technologies, Inc.Inventors: Nanibhushan Dattagupta, C. Nagaraja Sridhar, Whei-Kuo Wu
-
Patent number: 6182665Abstract: A method for predicting whether a pregnant woman will be able to carry a fetus to viability by determining her immunological responsiveness to recall antigens. Women, particularly women with a history of recurrent spontaneous abortion, who have a responsiveness that is no higher than the responsiveness of women known to have had a successful pregnancy, have a high probability of maintaining gestation until viability.Type: GrantFiled: May 29, 1998Date of Patent: February 6, 2001Assignee: Brigham and Women's HospitalInventors: Joseph A. Hill, Bonnie L. Bermas
-
Patent number: 6156522Abstract: Interstitial cystitis (IC) is a chronic bladder disease for which the exact etiology is unknown and for which there is no reliably effective treatment. However, it is known that the bladder epithelium is often abnormal in IC. We discovered that normal, adult, human bladder epithelial cells are inhibited from proliferating by an anti-proliferative fact (APF) present in IC urine specimens. Inhibited proliferation may cause epthelial abnormalities characteristic of IC such as ulcerations and multiple tears in the bladder epithelium. We further discovered that levels of heparin binding--epidermal growth factor-like growth fact (HB-EGF), a factor known be important for epithelial cell proliferation and wound healing in other tissues, are abnormally low in the urine of patients suffering from IC as compared to asymptomatic controls or patients with acute bacterial cystitis. The invention herein is directed to the use of urine levels of HB-EGF as a diagnostic marker for IC.Type: GrantFiled: July 2, 1998Date of Patent: December 5, 2000Assignee: University of Maryland BaltimoreInventors: Susan K. Keay, John W. Warren, Michael K. Hise
-
Patent number: 6153440Abstract: The present invention provides methods for the simultaneous measurement of triiodothyronine (T.sub.3) and thyroxine (T.sub.4) in biological fluids such as serum by direct equilibrium dialysis and immunoassay. Specifically, the method comprises dialyzing the serum sample to equilibrium in a physiological buffer system so that the free T.sub.3 and the free T.sub.4 are separated from T.sub.3 and T.sub.4 bound to serum proteins. The method further comprises combining a measured quantity of the dialyzed serum sample having free T.sub.3 and free T.sub.4 with reagents comprising a measured quantity of T.sub.3 labelled with a detectable marker and a measured quantity of T.sub.4 labelled with a detectable marker; an anti-T.sub.3 antibody of sufficient specificity and in sufficient quantity to bind a measurable quantity of the free T.sub.3, and an anti-T.sub.4 antibody of sufficient specificity and in sufficient quantity to bind a measurable quantity of the free T.sub.4.Type: GrantFiled: September 23, 1998Date of Patent: November 28, 2000Assignee: The Regents of the University of CaliforniaInventor: Inder J. Chopra
-
Patent number: 6143491Abstract: Method and compositions for treating type II diabetes; and type II diabetes diagnostics are disclosedType: GrantFiled: September 5, 1997Date of Patent: November 7, 2000Assignee: Millennium Pharmaceuticals, Inc.Inventor: M. Alexandra Glucksmann
-
Patent number: 6110692Abstract: A preparation containing a receptor for underivatized, aqueous soluble .beta.(1-3)-glucan is disclosed, along with characterization of the receptor for underivatized, aqueous soluble .beta.(1-3)-glucan. Also described are assays for identifying agents which alter the effect of underivatized, aqueous soluble .beta.(1-3)-glucan on activation of signal transduction pathways and agents identified thereby.Type: GrantFiled: January 31, 1997Date of Patent: August 29, 2000Assignee: The Collaborative Group, Ltd.Inventors: Eric Wakshull, William M. Mackin, Janet Zimmerman
-
Patent number: 6110675Abstract: A set of contiguous and partially overlapping RNA sequences and polypeptides encoded thereby, designated as PS112 and transcribed from prostate tissue is described. A fully sequenced clone representing a continuous sequence of PS112 is also disclosed. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the prostate, such as prostate cancer. Also provided are antibodies which specifically bind to PS112-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific PS112 polypeptide, which molecules are useful for the therapeutic treatment of prostate diseases, tumors or metastases.Type: GrantFiled: October 8, 1997Date of Patent: August 29, 2000Assignee: Abbott LaboratoriesInventors: Maurice Cohen, Paula N. Friedman, Julian Gordon, Steven C. Hodges, Michael R. Klass, Jon D. Kratochvil, Lisa Roberts-Rapp, John C. Russell, Stephen D. Stroupe, Hong Yu
-
Patent number: 6096502Abstract: A UL9 substrate for detecting helicase activity in a UL9 protein is provided. In one embodiment, the substrate includes a first strand including a herpes replication origin sequence and a first single stranded tail; and a second strand including a sequence complementary to the herpes replication origin sequence. In one variation, the first single stranded tail is 3' relative to the herpes replication origin sequence. The second strand may optionally further include a single stranded tail. The single stranded tail on the second strand may be 3' or 5' relative to the sequence complementary to the herpes replication origin sequence. In another variation, the first single stranded tail is 5' relative to the herpes replication origin sequence. The second strand may optionally further include a single stranded tail. The single stranded tail on the second strand may be 3' or 5' relative to the sequence complementary to the herpes replication origin sequence.Type: GrantFiled: March 30, 1998Date of Patent: August 1, 2000Assignee: Sam S.-K. LeeInventor: Sam S.-K. Lee
-
Patent number: 6090938Abstract: A preparation containing a receptor for underivatized, aqueous soluble .beta.(1-3)-glucan is disclosed, along with characterization of the receptor for underivatized, aqueous soluble .beta.(1-3)-glucan. Also described are assays for identifying agents which alter the effect of underivatized, aqueous soluble .beta.(1-3)-glucan on activation of signal transduction pathways and agents identified thereby.Type: GrantFiled: June 14, 1996Date of Patent: July 18, 2000Assignee: Collaborative Group, Ltd.Inventors: Eric Wakshull, William M. Mackin, Janet Zimmerman
-
Patent number: 6090408Abstract: Polymerized liposome particles which are linked to a targeting agent and may also be linked to a contrast enhancement agent and/or linked to or encapsulating a treatment agent. The targeting imaging enhancement polymerized liposome particles interact with biological targets holding the image enhancement agent to specific sites providing in vitro and in vivo study by magnetic resonance, radioactive, x-ray or optical imaging of the expression of molecules in cells and tissues during disease and pathology. Targeting polymerized liposomes may be linked to or encapsulate a treatment agent, such as, proteins, drugs or hormones for directed delivery to specific biological sites for treatment.Type: GrantFiled: July 27, 1998Date of Patent: July 18, 2000Assignee: Targesome, Inc.Inventors: King Chuen Li, Mark David Bednarski, Richard Wood Storrs, Henry Y. Li, Francois Daniel Tropper, Curtis Kang Hoon Song, Dorothy Anna Sipkins, Jeremy Kenji Kuniyoshi
-
Patent number: 6090560Abstract: The present invention relates to novel mammalian amino acid transporter proteins and the genes that encode such proteins. The invention is directed toward the isolation, characterization and pharmacological use of a human amino acid transporter protein termed EAAT4 and genes encoding such a transporter. The invention specifically provides isolated complementary DNA copies of mRNA corresponding to this transporter gene. Also provided are recombinant expression constructs capable of expressing this amino acid transporter gene in cultures of transformed prokaryotic and eukaryotic cells, as well as such cultures of transformed cells that synthesize the human amino acid transporter protein encoded therein. The invention also provides methods for screening in vitro compounds having transport-modulating properties using preparations of transporter proteins from such cultures of cells transformed with recombinant expression constructs.Type: GrantFiled: November 9, 1998Date of Patent: July 18, 2000Assignee: Oregon Health Sciences UniversityInventors: Susan G. Amara, Jeffrey L. Arriza, Wendy A. Fairman
-
Patent number: 6080549Abstract: Methods for detecting schizophrenia or depression based on modifications of the contribution of the D.sub.4 receptor to phospholipid methylation levels are described herein. Individuals with schizophrenia or depression have a deficiency in phospholipid methylation activity compared with normal individuals. Methods for screening therapeutic processes or agents for use in treatment of schizophrenia or related neuropsychiatric disorders are also described.Type: GrantFiled: April 8, 1997Date of Patent: June 27, 2000Assignee: Northeastern UniversityInventor: Richard C. Deth
-
Patent number: 6074828Abstract: The present invention relates to novel mammalian amino acid transporter proteins and the genes that encode such proteins. The invention is directed toward the isolation, characterization and pharmacological use of the human amino acid transporter proteins EAAT1, EAAT2, EAAT3 and ASCT1. The invention specifically provides isolated complementary DNA copies of mRNA corresponding to each of these transporter genes. Also provided are recombinant expression constructs capable of expressing each of the amino acid transporter genes of the invention in cultures of transformed prokaryotic and eukaryotic cells, as well as such cultures of transformed cells that synthesize the human amino acid transporter proteins encoded therein. The invention also provides methods for screening in vitro compounds having transport-modulating properties using preparations of transporter proteins from such cultures of cells transformed with recombinant expression constructs.Type: GrantFiled: March 17, 1998Date of Patent: June 13, 2000Assignee: Oregon Health Sciences UniversityInventors: Susan G. Amara, Jeffrey L. Arriza
-
Patent number: 6071493Abstract: The present invention is directed to screening for an agent that inhibits mononuclear phagocyte-plaque component complex formation (hereinafter "complex formation"). The methods include the steps of contacting a mononuclear phagocyte with a plaque component to stimulate complex formation and adding an agent suspected of inhibiting complex formation, measuring complex formation, and comparing complex formation to a measured control, wherein the reduction of complex formation compared to the control results in detection of an agent that inhibits complex formation. The mononuclear phagocytes may be from mammalian brain. The plaque component may be coupled to a solid support.Type: GrantFiled: September 20, 1996Date of Patent: June 6, 2000Assignee: Baylor College of MedicineInventor: Dana Giulian
-
Patent number: 6063912Abstract: Expression of the polynucleotide molecule, Psx, is restricted to placenta, and in particular, to placenta trophoblast cell layers during embryogenesis. The expression pattern of Psx is exploited to detect trophoblast specific lineages, such as labyrinthine trophoblast layer and giant cells. The invention provides an isolated DNA molecule encoding Psx protein, and chimeric constructs, vector and host cells containing the isolated DNA. Also provided is a method for identifying putative abortion-inducing agents, which may offer an alternative to surgical abortion.Type: GrantFiled: August 6, 1998Date of Patent: May 16, 2000Assignee: Korea Kumho Petrochemical Co., Ltd.Inventors: Jong-Yoon Chun, Yun-Jeong Han
-
Patent number: 6057102Abstract: Entry of HIV-1 into target cells requires cell surface CD4 as well as additional host cell cofactors. A cofactor required for infection with virus adapted for growth in transformed T cell lines was recently identified and named fusin. Fusin, however, does not promote entry of macrophage-tropic viruses that are believed to be the key pathogenic strains in vivo. It has now been determined that the principal cofactor for entry mediated by the envelope glycoproteins of primary macrophage-tropic strains of HIV-1 is CC-CKR5, a receptor for the .beta.-chemokines RANTES, MIP-1.alpha., and MIP-1.beta.. It has also been found that individuals who are homozygous for a mutation of the CKR-5 receptor are resistent to HIV infection; in vitro infection requires a 1000-fold higher dose of HIV than normal cells. The mutation results in complete suppression of CKR-5 expression.Type: GrantFiled: August 8, 1997Date of Patent: May 2, 2000Assignee: The Aaron Diamond Aids Research CenterInventors: Nathaniel R. Landau, Richard A. Koup, Rong Liu, William Paxton
-
Patent number: 6054282Abstract: A method for the detection of a compound which modulates binding of a ligand to a biological receptor, which method comprises contacting the ligand, biological receptor and test compound at a locus on a solid phase matrix, the matrix allowing movement of fluids therein by capillary action, under conditions which permit binding of the ligand to the biological receptor and partition of any unbound ligand on the solid phase matrix, and detecting any modulation of binding by the test compound by reference to any such partition.Type: GrantFiled: February 14, 1996Date of Patent: April 25, 2000Assignee: Zeneca LimitedInventor: Andrew John Garman
-
Patent number: 6048703Abstract: Methods for the biochemical and immunohistochemical detection of cell apoptosis are described. The methods utilize the detection and measurement of polypeptide fragments generated during apoptosis. Conditions associated with apoptosis may be detected by the methods of this invention. Methods are also presented for the screening of potential therapeutic compounds which inhibit or stimulate apoptosis. Kits for detection of apoptosis and diagnosis of diseases are also provided.Type: GrantFiled: November 12, 1997Date of Patent: April 11, 2000Assignee: Cephalon, Inc.Inventors: Robert Siman, Donna Bozyczko-Coyne, Sheryl L. Meyer, Ratan Venkatraman Bhat
-
Patent number: 6037185Abstract: A non-competitive method for the determination of analytes. Initially the analyte is bound to a specific binding partner, after which the unoccupied binding sites of the binding partner are inactivated. The bound analyte is then dissociated from the binding partner and replaced by a labeled marker, after which the bound labeled marker is determined. The signal from the bound labeled marker is directly proportional to the initial amount of analyte in the sample, which makes the present method more favorable than the competitive assays.Type: GrantFiled: July 8, 1998Date of Patent: March 14, 2000Assignees: Wallac Oy, Orion-yhtyma OyInventor: Petri Saviranta
-
Patent number: 6022693Abstract: A method for the direct analysis of the presence of an analyte which becomes embedded in keratinized structures, e.g., hair, fingernails and toenails, from the bloodstream of a subject which comprises preparing a mixture containing dithiothreitol or dithioerythritol ("DTT"), an enzyme suitable for the digestion of the keratin structure and a sample of the keratin structure; permitting the enzyme to digest the sample of keratin structure to form a digest solution, followed by the addition of a salt of a metal of copper, zinc, manganese, iron, lead, cadmium, mercury, silver and cobalt to deactivate the DTT; and finally subjecting the digest solution to analysis to determine the presence of the analyte in the keratin structure sample. The protease enzymes papain, chymopapain, and proteinase K are preferred for use in the invention.Type: GrantFiled: March 6, 1997Date of Patent: February 8, 2000Assignee: Psychemedics CorporationInventor: Werner Andreas Baumgartner
-
Patent number: 5998150Abstract: The present invention provides a method of determining the status of a multiple sclerosis patient, i.e., predicting the transition from a status of relapsing-remitting to a progressive phase of multiple sclerosis, comprising the step of measuring the levels of urinary myelin basic protein-like material in the patient. The present invention also provides a method of determining the amount of lesions and total lesion area of a multiple sclerosis patient, comprising the step of measuring the levels of urinary myelin basic protein-like material in the patient. Further provided is a method of monitoring myelination in a developing child, comprising the step of: measuring the levels of myelin basic protein-like material in the urine of said child.Type: GrantFiled: October 1, 1996Date of Patent: December 7, 1999Assignee: UAB Research FoundationInventors: John Nicholas Whitaker, Robert David Kachelhofer, Beverly Ann Layton, Edwin Luther Bradley, Jr., Sheila Loughran Burgard, Anthony Thomas Reder, Wendy Jean Morrison, Guojun Zhao, Donald Winston Paty
-
Patent number: 5993777Abstract: The present invention relates to a class of compounds having affinity for certain cancer cells, e.g. lung carcinomas, colon carcinomas, renal carcinomas, prostate carcinomas, breast carcinomas, malignant melanomas, gliomas, neuroblastomas and pheochromocytomas. The compounds of the present invention can also bind with high specificity to cell surface sigma receptors and can therefore be used for diagnostic imaging of any tissue having an abundance of cells with sigma receptors. The present invention provides such compounds as agents for diagnostic imaging and for detecting and treating tumors containing the cancer cells described above.Type: GrantFiled: June 6, 1995Date of Patent: November 30, 1999Assignee: Research Corporation Technologies, Inc.Inventors: Christy S. John, Jesse Baumgold, John G. McAfee, Terry Moody, Wayne Bowen
-
Patent number: 5989825Abstract: This invention relates to novel mammalian excitatory amino acid transporter proteins and genes encoding such proteins. The invention is directed towards the isolation, characterization and use of human excitatory amino acid transporter proteins for pharmacological screening of analogues, agonists, antagonists, inhibitors, modulators and facilitators of excitatory amino acid transport in a variety of tissues, particularly neuronal tissues. This invention provides isolated nucleic acid encoding a novel excitatory amino acid transporter subtype that is specifically expressed in retina. Also provided are recombinant expression constructs capable of expressing this novel transporter in transformed prokaryotic and eukaryotic cells, and also provides such transformed cell cultures producing the novel human transporter. Purified transporter protein and membranes comprising the transporter protein are also provided.Type: GrantFiled: November 9, 1998Date of Patent: November 23, 1999Assignee: Oregon Health Sciences UniversityInventors: Susan G. Amara, Jeffrey L. Arriza, Scott Eliasof, Michael P. Kavanaugh
-
Patent number: 5972622Abstract: This invention relates to antibodies or fragments thereof that can be used as indicators of apoptosis. More specifically, this invention relates to antibodies and fragments thereof that selectively bind GP46, a protein whose levels increase significantly upon induction of apoptosis. This invention also relates to the hybridomas that produce anti-GP46 monoclonal antibodies. This invention also discloses a method of detecting cell death by apoptosis in vitro or in vivo by detecting and quantifying GP46 present in biological samples, comprising contacting the sample with the antibodies or fragments to form GP46 immunocomplexes, which may then be detected by the use of known methods. This detection method is useful for research into apoptosis and research relating to diseases in which apoptosis is involved. This method could also be used to diagnose the extent of damage caused by a particular disease or to evaluate the efficacy of drug treatments.Type: GrantFiled: February 6, 1997Date of Patent: October 26, 1999Inventor: Louise Desjardins
-
Patent number: 5955287Abstract: A method of performing immunoassay to detect the level of target proteins common to various malignancies including metallopanstimulin or metallopanstimulin-like materials as well as complement components, in a biologic sample is provided wherein the protein molecules in the patient sample compete with radiolabeled peptide for sites on the Anti-peptide-specific antibody. The amount of radioactivity measured is inversely proportional to the concentration of protein molecules present in the patient sample, which is determined from a standard curve. Another method includes determining the presence of a protein elevated in the serum of patients with neoplasms by the detection of the interference of binding or precipitation of a first antibody by a second antibody by the target protein.Type: GrantFiled: September 12, 1997Date of Patent: September 21, 1999Inventor: Jose Alberto Fernandez-Pol
-
Patent number: 5919628Abstract: The present invention relates to novel mammalian amino acid transporter proteins and the genes that encode such proteins. The invention is directed toward the isolation, characterization and pharmacological use of the human amino acid transporter proteins EAAT1, EAAT2, EAAT3 and ASCT1. The invention specifically provides isolated complementary DNA copies of mRNA corresponding to each of these transporter genes. Also provided are recombinant expression constructs capable of expressing each of the amino acid transporter genes of the invention in cultures of transformed prokaryotic and eukaryotic cells, as well as such cultures of transformed cells that synthesize the human amino acid transporter proteins encoded therein. The invention also provides methods for screening in vitro compounds having transport-modulating properties using preparations of transporter proteins from such cultures of cells transformed with recombinant expression constructs.Type: GrantFiled: March 17, 1998Date of Patent: July 6, 1999Assignee: Oregon Health Sciences UniversityInventors: Susan G. Amara, Jeffrey L. Arriza
-
Patent number: 5919638Abstract: A set of contiguous and partially overlapping oligonucleotide sequences transcribed from a prostate. Also provided are human disease-specific polypeptides translated from said oligonucleotide sequences and a procedure for producing such polypeptide by recombinant techniques. Antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat prostate diseases, tumors or metastastases are disclosed. Also disclosed is the use of said antibodies, agonists and inhibitors as well as the nucleic acid sequences to screen for, diagnose, prognose, stage and monitor conditions and diseases attributable to prostate tumor, especially prostate cancer. The use of said partial sequence to provide antibodies, agonists and inhibitors as well as partial nucleic acid sequences to screen for, diagnose, stage and monitor diseases and associated with prostate tumor.Type: GrantFiled: October 8, 1996Date of Patent: July 6, 1999Assignee: Abbott LaboratoriesInventors: John C. Russell, Maurice Cohen, Paula N. Friedman, Michael R. Klass, Lisa Roberts-Rapp
-
Patent number: 5856201Abstract: A cellulose binding domain (CBD) having a high affinity for crystalline cellulose and chitin is disclosed, along with methods for the molecular cloning and recombinant production thereof. Fusion products comprising the CBD and a second protein are likewise described. A wide range of applications are contemplated for both the CBD and the fusion products, including drug delivery, affinity separations, and diagnostic techniques.Type: GrantFiled: October 27, 1994Date of Patent: January 5, 1999Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem, The University of CaliforniaInventors: Oded Shoseyov, Itai Shpiegl, Marc A. Goldstein, Roy H. Doi
-
Patent number: 5854081Abstract: Stable over-expression of native and hexahistidine/FLAG extended recombinant human adenosine receptors permits recovery of membranes and membrane fragments bearing a high density of adenosine receptors. Cell lines expressing all four sub-types of human adenosine receptors have been identified. The receptors, and membranes and membrane fragments bearing the same, can be used in assays to screen compounds for binding ability to the adenosine receptors, such as potential pharmaceutical agents.Type: GrantFiled: June 20, 1996Date of Patent: December 29, 1998Assignee: The University of Patent FoundationInventors: Joel Linden, Heidi Taylor, Anna Robeva, Robin Woodard, Xiaowei Jin
-
Patent number: 5851783Abstract: A method and kit are described that are useful in the diagnosis of amyotrophic lateral sclerosis or the evaluation of its progression. According to the method, a purified voltage-sensitive calcium channel complex is contacted with a biological fluid obtained from a person suspected of having, or known to have, amyotrophic lateral sclerosis. The voltage-sensitive calcium channel is of a type that ALS sera selectively reacts with. The reaction takes place for a time and under conditions sufficient for the calcium channel complex and anti-calcium channel complex antibodies that may be present in the biological fluid to form an antigen/antibody complex. The presence or absence of the antigen/antibody complex is then determined.Type: GrantFiled: February 13, 1995Date of Patent: December 22, 1998Assignee: Baylor College of MedicineInventors: Stanley H. Appel, R. Glenn Smith, Enrico Stefani
-
Patent number: 5846959Abstract: A method for the treatment of cardiovascular diseases and noncardiovascular inflammatory diseases that are mediated by VCAM-1 is provided that includes the removal, decrease in the concentration of, or prevention of the formation of oxidized polyunsaturated fatty acids, or interferes with a complex formed between a polyunsaturated fatty acid or an oxidized polyunsaturated fatty acid and a protein or peptide that mediates the expression of VCAM-1. A method is also provided for suppressing the expression of a redox-sensitive gene or activating a gene that is suppressed through a redox-sensitive pathway, that includes administering an effective amount of a substance that prevents the oxidation of the oxidized signal, and typically, the oxidation of a polyunsaturated fatty acid, or interferes with a complex formed between the oxidized signal and a protein or peptide that mediates the expression of the redox gene.Type: GrantFiled: June 6, 1995Date of Patent: December 8, 1998Assignee: Emory UniversityInventors: Russell M. Medford, R. Wayne Alexander, Sampath Parthasarathy, Bobby V. Khan
-
Patent number: 5821260Abstract: Dithiocarboxylates, and in particular, dithiocarbamates, block the induced expression of the endothelial cell surface adhesion molecule VCAM-1, and are therefor useful in the treatment of cardiovascular disease, including atherosclerosis, post-angioplasty restenosis, coronary artery diseases, and angina, as well as noncardiovascular inflammatory diseases that are mediated by VCAM-1.Type: GrantFiled: June 7, 1995Date of Patent: October 13, 1998Assignee: Emory UniversityInventors: Russell M. Medford, Margaret K. Offermann, R. Wayne Alexander, Sampath Parthasarathy
-
Patent number: 5811072Abstract: Additives are proposed for compositions comprising radiolabelled organic compounds e.g. 32P-labelled nucleotides. Stabilisers are selected from tryptophan, para-aminobenzoate, indoleacetate and the azole group. Dyes are selected from Sulphorhodamine B, Xylene Cyanol, Azocarmine B and New Coccine. Preferred compositions contain both stabiliser and dye.Type: GrantFiled: May 6, 1997Date of Patent: September 22, 1998Assignee: Amersham Pharmacia Biotech UK LimitedInventors: Roger Malcolm Price, Christopher Charles May, Elizabeth Margaret Buckley, Timothy Stone
-
Patent number: 5807884Abstract: A method for the treatment of cardiovascular diseases and noncardiovascular inflammatory diseases that are mediated by VCAM-1 is provided that includes the removal, decrease in the concentration of, or prevention of the formation of oxidized polyunsaturated fatty acids, or interferes with a complex formed between a polyunsaturated fatty acid or an oxidized polyunsaturated fatty acid and a protein or peptide that mediates the expression of VCAM-1. A method is also provided for suppressing the expression of a redox-sensitive gene or activating a gene that is suppressed through a redox-sensitive pathway, that includes administering an effective amount of a substance that prevents the oxidation of the oxidized signal, and typically, the oxidation of a polyunsaturated fatty acid, or interferes with a complex formed between the oxidized signal and a protein or peptide that mediates the expression of the redox gene.Type: GrantFiled: October 4, 1994Date of Patent: September 15, 1998Assignee: Emory UniversityInventors: Russell M. Medford, R. Wayne Alexander, Sampath Parthasarathy, Bobby V. Khan